Brief: HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG
09/05/2023 14:14
May 9 (Reuters) - Heart Test Laboratories Inc HSCS.O :
* HEARTSCIENCES ANNOUNCES COMPLETION OF PATIENT ENROLLMENT
FOR FDA
PIVOTAL STUDY OF MYOVISTA WAVECG
Source text for Eikon: ID:nGNX4L6jJm
Further company coverage: HSCS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HeartSciences
See all newsBrief: Heartsciences Files Definitive Proxy Statement For Proposed Business Combination With Fortitude Mining
Brief: Fortitude Provides Second Quarter 2026 Financial And Operating Highlights
Brief: Fortitude Invests $1.0 Million In Heartsciences At A 22% Premium With No Adjustment To The Merger Consideration
Brief: Heartsciences - Files Preliminary Proxy For Business Combination With Fortitude Mining Holdings
Brief: Heartsciences Signs First Saas Revenues Agreement Following Full Launch Of Myovista Insights™